Recruitment activity has stopped within the AMYPAD Diagnostic and Patient Management Study (DPMS) during the past months. This was due to the closure of sites and cessation of research visits as a result of the global COVID-19 crisis. During this time, the sites were able to focus on the data quality check and the team has continued to work on data cleaning to allow moving forward with the analysis. The preliminary analyses of the AMYPAD DPMS participants’ baseline features is ongoing and first data will be presenting later this month at the AAIC conference.

Now that infection rates are dropping across Europe, hospitals in many countries are starting to resume regular care. More importantly, various centers have restarted recruiting and scanning subjects for the DPMS, which is exciting news. Recruitment has restarted in Switzerland, Germany and the Netherlands while France and Spain is getting ready to restart in July. The scanning has restarted in Switzerland, Germany, the Netherlands and France. In addition, visits continue to be performed on the phone/by post to collect as many data as possible and avoid face-to-face visit when possible.

762 participants have been screened in the study so far in 7 European countries (Switzerland, Netherlands, Spain, France, Sweden, Germany and UK) of which 544 have been scanned. 12 participants have already received a second scan. The DPMS will recruit 900 participants and need less than 150 participants to complete. Participants will be followed-up to determine the usefulness of ß-amyloid imaging with regards to diagnostic confidence, decision trees, change in diagnosis and alternations between planned and actual patient management plans.